Ultragenyx Pharmaceutical granted 65,886 restricted stock units to 39 newly hired non-executive officers under its Employment Inducement Plan. The awards, approved by the compensation committee with a grant date of July 16, 2026, vest over four years with 25% of the underlying shares vesting on each anniversary of the grant date, subject to continued employment. The grants were made as an inducement material to the new employees entering into employment in accordance with Nasdaq Listing Rule 5635(c)(4).
UltragenyxGrant of restricted stock units to new hires, dilutive but standard inducement; no clear impact on business performance.